How Guardant360 CDx detects ESR1 mutations before breast cancer progresses on imaging
Guardant360 CDx gains European CE marking for ETCAMAH patient selection. See how ESR1 blood testing changes advanced breast cancer treatment.
Medical Devices & Diagnostics
Features & Analysis
AstraZeneca’s Etcamah worked when an ESR1 mutation appeared. Why did the broader first-line trial fail?
AstraZeneca has secured FDA accelerated approval for Etcamah after SERENA-6 showed that switching therapy when an ESR1 mutation emerged in circulating tumour DNA sharply delayed disease progression. Days later, however, the broader SERENA-4 first-line trial missed its primary endpoint, creating an unusually clear demonstration that patient selection and treatment timing may matter as much as
Pharma & Biotech
AstraZeneca’s Etcamah wins FDA approval after cutting progression risk 56%. What changes for breast cancer care?
Etcamah can be started before visible progression when ESR1 resistance emerges. The bigger change may be how often breast cancer is tested.
Pharma & Biotech
FDA approves AstraZeneca Etcamah after ctDNA detects breast cancer resistance before scans
FDA approves Etcamah after an ESR1 mutation is detected in blood before breast cancer progresses on scans, creating a first for ctDNA-guided treatment.
Pharma & Biotech
Why AstraZeneca’s EMERALD-3 and SERENA-6 data could influence future standards of cancer care
Could AstraZeneca’s latest ASCO 2026 cancer data reshape future treatment sequencing in liver and breast oncology? Read the full analysis.